<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66952">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01671839</url>
  </required_header>
  <id_info>
    <org_study_id>CP-01-1004</org_study_id>
    <nct_id>NCT01671839</nct_id>
  </id_info>
  <brief_title>Study of the Cabochon System for Improvement in the Appearance of Cellulite</brief_title>
  <official_title>Pivotal Study of the Cabochon System for Improvement in the Appearance of Cellulite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cabochon Aesthetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cabochon Aesthetics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the Cabochon System
      for the improvement in the appearance of cellulite.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in cellulite severity</measure>
    <time_frame>Treatment to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in cellulite severity as determined in an independent physician assessment of subject photographs taken before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safe Treatment</measure>
    <time_frame>Treatment to 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Freedom from serious adverse events directly attributable to the Cabochon System or procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved Appearance</measure>
    <time_frame>Treatment to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Independent physician assessment of subject photographs taken before and after treatment according to Global Aesthetic Improvement Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>Treatment to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject rated satisfaction according to a 5 point Likert scale after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Tolerability</measure>
    <time_frame>Treatment to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject rated pain according to a 0-10 numerical rating scale.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Gynoid Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Subcutaneous tissue release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Subcutaneous tissue release with the Cabochon System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subcutaneous tissue release with the Cabochon System</intervention_name>
    <description>Device: Subcutaneous tissue release</description>
    <arm_group_label>Subcutaneous tissue release</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age 18-55

          -  moderate or severe cellulite

          -  BMI less than 35

          -  will not to try any other cellulite treatments through 12M follow-up

        Exclusion Criteria:

          -  cellulite treatment on the thighs or buttocks in the last 90 days

          -  prior liposuction in the thighs or buttocks

          -  Greater than 10% increase or decrease in body weight within past 6 months

          -  evidence of active infection or a fever &gt;38C

          -  current or recent smoker

          -  history of hypertension, diabetes or hypoglycemia

          -  history of coagulopathy(ies) and/or on anticoagulant medication

          -  history of cardiopathy or pneumopathy

          -  history of severe anemia

          -  has atrophic scars, or has a history of atrophic scars or keloids

          -  taken within 14 days of treatment:

               -  NSAIDs (e.g. aspirin, ibuprofen, naproxen)

               -  Vitamin E, dietary supplements (e.g. Gingko Biloba, willow bark)

               -  Herbal Teas

          -  Subject is pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Kaminer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Care Physicians</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Coleman Center for Cosmetic and Dermatologic Surgery</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser Skin &amp; Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkinCare Physicians</name>
      <address>
        <city>Chestnut Hill,</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 10, 2012</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
